165 related articles for article (PubMed ID: 28495083)
1. Design and synthesis of potent inhibitors of the mono(ADP-ribosyl)transferase, PARP14.
Upton K; Meyers M; Thorsell AG; Karlberg T; Holechek J; Lease R; Schey G; Wolf E; Lucente A; Schüler H; Ferraris D
Bioorg Med Chem Lett; 2017 Jul; 27(13):2907-2911. PubMed ID: 28495083
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of potent and selective inhibitors of mono-(ADP-ribosyl)transferases PARP10 and PARP14.
Holechek J; Lease R; Thorsell AG; Karlberg T; McCadden C; Grant R; Keen A; Callahan E; Schüler H; Ferraris D
Bioorg Med Chem Lett; 2018 Jun; 28(11):2050-2054. PubMed ID: 29748053
[TBL] [Abstract][Full Text] [Related]
3. Structure, Function and Inhibition of Poly(ADP-ribose)polymerase, Member 14 (PARP14).
Schweiker SS; Tauber AL; Sherry ME; Levonis SM
Mini Rev Med Chem; 2018; 18(19):1659-1669. PubMed ID: 30112992
[TBL] [Abstract][Full Text] [Related]
4.
Kam CM; Tauber AL; Oosthuizen DL; Levonis SM; Schweiker SS
Future Med Chem; 2020 Dec; 12(23):2105-2122. PubMed ID: 33225737
[No Abstract] [Full Text] [Related]
5. Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.
Kam CM; Tauber AL; Levonis SM; Schweiker SS
Future Med Chem; 2020 Dec; 12(24):2179-2190. PubMed ID: 33225736
[TBL] [Abstract][Full Text] [Related]
6. Analogs of TIQ-A as inhibitors of human mono-ADP-ribosylating PARPs.
Maksimainen MM; Murthy S; Sowa ST; Galera-Prat A; Rolina E; Heiskanen JP; Lehtiö L
Bioorg Med Chem; 2021 Dec; 52():116511. PubMed ID: 34801828
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule Microarray Based Discovery of PARP14 Inhibitors.
Peng B; Thorsell AG; Karlberg T; Schüler H; Yao SQ
Angew Chem Int Ed Engl; 2017 Jan; 56(1):248-253. PubMed ID: 27918638
[TBL] [Abstract][Full Text] [Related]
8. PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities.
Đukić N; Strømland Ø; Elsborg JD; Munnur D; Zhu K; Schuller M; Chatrin C; Kar P; Duma L; Suyari O; Rack JGM; Baretić D; Crudgington DRK; Groslambert J; Fowler G; Wijngaarden S; Prokhorova E; Rehwinkel J; Schüler H; Filippov DV; Sanyal S; Ahel D; Nielsen ML; Smith R; Ahel I
Sci Adv; 2023 Sep; 9(37):eadi2687. PubMed ID: 37703374
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2.
Moustakim M; Riedel K; Schuller M; Gehring AP; Monteiro OP; Martin SP; Fedorov O; Heer J; Dixon DJ; Elkins JM; Knapp S; Bracher F; Brennan PE
Bioorg Med Chem; 2018 Jul; 26(11):2965-2972. PubMed ID: 29567296
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
[TBL] [Abstract][Full Text] [Related]
12.
S Schweiker S; L Tauber A; M Levonis S
Future Med Chem; 2020 Oct; 12(19):1729-1741. PubMed ID: 33032449
[No Abstract] [Full Text] [Related]
13. Identification of Poly(ADP-Ribose) Polymerase Macrodomain Inhibitors Using an AlphaScreen Protocol.
Ekblad T; Verheugd P; Lindgren AE; Nyman T; Elofsson M; Schüler H
SLAS Discov; 2018 Apr; 23(4):353-362. PubMed ID: 29316839
[TBL] [Abstract][Full Text] [Related]
14. Activity-based assay for human mono-ADP-ribosyltransferases ARTD7/PARP15 and ARTD10/PARP10 aimed at screening and profiling inhibitors.
Venkannagari H; Fallarero A; Feijs KL; Lüscher B; Lehtiö L
Eur J Pharm Sci; 2013 May; 49(2):148-56. PubMed ID: 23485441
[TBL] [Abstract][Full Text] [Related]
15. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of PARP10 using a chemical genetics strategy.
Morgan RK; Carter-O'Connell I; Cohen MS
Bioorg Med Chem Lett; 2015 Nov; 25(21):4770-4773. PubMed ID: 26231158
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in PARP14 research.
Tauber AL; Levonis SM; Schweiker SS
Future Med Chem; 2020 Sep; 12(18):1657-1667. PubMed ID: 32893678
[TBL] [Abstract][Full Text] [Related]
18. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.
Velagapudi UK; Langelier MF; Delgado-Martin C; Diolaiti ME; Bakker S; Ashworth A; Patel BA; Shao X; Pascal JM; Talele TT
J Med Chem; 2019 Jun; 62(11):5330-5357. PubMed ID: 31042381
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of pyridazino[3,4,5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors.
Wang J; Tan H; Sun Q; Ge Z; Wang X; Wang Y; Li R
Bioorg Med Chem Lett; 2015 Jun; 25(11):2340-4. PubMed ID: 25899312
[TBL] [Abstract][Full Text] [Related]
20. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
